RenovoRx Executes Definitive Subscription Agreement With Accredited Investors For $11.1M At Market Private Placement

4/8/24 8:36:43 AM ET

$RNXT

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RNXT alert in real time by email

Cash position now expected to fund current operating plan into 2026
Financing provides cash runway to advance the ongoing pivotal Phase III TIGeR-PaC trial through the second interim readout and towards completion of the trial
Financing also enables the expansion of RenovoRx's TAMP™ (Trans-Arterial Micro-Perfusion) clinical development pipeline into additional cancer indications

Get the next $RNXT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RNXT

Date	Price Target	Rating	Analyst
11/1/2021	$16.00	Buy	Roth Capital
10/6/2021	$15.00	Buy	Maxim Group

More analyst ratings

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company's foundational FDA
6/10/24 8:30:00 AM ET
$IMMX
$RNXT
Biotechnology: Pharmaceutical Preparations
Health Care
RenovoRx Closes $6.1 Million Private Placement
With Material Participation From Insiders, Offering Proceeds to Help Drive Company Towards Second Interim Analysis of the Pivotal TIGeR-PaC Phase III Clinical Trial by Late 2024 RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that it has closed a private placement (the "private placement" or the "financing") resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses. The closing of this private placement extends RenovoRx's cash runway as RenovoRx continues its ongoing pivotal TIGeR-PaC Phase III c
1/29/24 8:30:00 AM ET
$RNXT
Biotechnology: Pharmaceutical Preparations
Health Care
RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.
RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company's Scientific Advisory Board (SAB). Dr. Ducreux is the Head of the Gastrointestinal Oncology Unit and Gastrointestinal Oncology Tumor Board at Gustave Roussy, Professor of Oncology at Paris-Saclay University in France, and Vice-Chair of ESMO GI. Dr. Ducreux was trained in medicine, gastroenterology, and gastrointestinal tract oncology at the University of Paris Sud. Dr. Ducreux earned his master's degree in biological sciences and PhD in health sciences. He has held pre
11/16/23 8:35:00 AM ET
$RNXT
Biotechnology: Pharmaceutical Preparations
Health Care

$RNXT
Press Releases

Fastest customizable press release news feed in the world

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company's foundational FDA
6/10/24 8:30:00 AM ET
$IMMX
$RNXT
Biotechnology: Pharmaceutical Preparations
Health Care
Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx's TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery
Data shows that the Trans-Arterial Micro-Perfusion (TAMP) platform increases intra-arterial pressure, improving drug delivery with 100-fold increase local tissue concentration of the therapy TAMP offers the potential to increase efficacy, improve safety and widen therapeutic window of drugs or other agents RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced a publication of pre-clinical studies supporting the efficacy and drug delivery mechanism of RenovoRx's Trans-Arterial Micro-Perfusion ("TAMP") therapy platform. The data was publis
5/21/24 9:00:00 AM ET
$RNXT
Biotechnology: Pharmaceutical Preparations
Health Care
RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024
RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai, Chief Executive Officer, will participate in a fireside chat at Alliance Global Partners (A.G.P.) Virtual Healthcare Company Showcase hosted by Scott Henry, Managing Director and Healthcare Analyst at A.G.P. The event will be held on Tuesday, May 21, 2024. Mr. Bagai will discuss recent corporate milestones, including the completion of private placements in January and April 2024 in which RenovoRx raised $17.2 million in total gross proceeds. The financing provides Reno
5/14/24 9:00:00 AM ET
$RNXT
Biotechnology: Pharmaceutical Preparations
Health Care

RenovoRx Executes Definitive Subscription Agreement With Accredited Investors For $11.1M At Market Private Placement

Chat with this insight

Recent Analyst Ratings for $RNXT

$RNXT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Roth Capital initiated coverage on RenovoRx with a new price target

Maxim Group initiated coverage on RenovoRx with a new price target

$RNXT Leadership Updates

Live Leadership Updates

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

RenovoRx Closes $6.1 Million Private Placement

RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.

$RNXT Market Insights

Live Market Insights

RenovoRx Publishes "Treatment of Locally Advanced Pancreatic Cancer (LAPC) Using Localized Trans-Arterial Micro Perfusion (TAMP™) of Gemcitabine: Combined Analysis of RR1 and RR2" In The Oncologist

University of Nebraska Medical Center To Enroll Patients For RenovoRx's Phase III TIGeR-PaC Clinical Trial

Ascendiant Capital Initiates Coverage On RenovoRx with Buy Rating, Announces Price Target of $8

$RNXT Press Releases

Fastest customizable press release news feed in the world

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx's TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery

RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024

$RNXT SEC Filings

RenovoRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by RenovoRx Inc.

RenovoRx Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

$RNXT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Ryan Una S

SEC Form 4 filed by Director Spiegel Robert J.

SEC Form 4 filed by Director Marton Laurence

$RNXT Large Ownership Changes

This live feed shows all institutional transactions in real time.

$RNXT Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

SEC Form SC 13G/A filed by RenovoRx Inc. (Amendment)

SEC Form SC 13G filed by RenovoRx Inc.

SEC Form SC 13G filed by RenovoRx Inc.

Agah Ramtin bought 40,983 shares, increasing direct ownership by 633% to 47,460 units (SEC Form 4)

Spiegel Robert J. bought 40,983 shares (SEC Form 4)

Bagai Shaun bought 40,983 shares, increasing direct ownership by 16% to 292,540 units (SEC Form 4)

Recent Analyst Ratings for
$RNXT

$RNXT
Analyst Ratings

$RNXT
Leadership Updates

$RNXT
Market Insights

$RNXT
Press Releases

$RNXT
SEC Filings

$RNXT
Insider Trading

$RNXT
Large Ownership Changes

$RNXT
Insider Purchases